Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Arena Pharmaceutical's third quarter 2024 earnings call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require appropriate assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Andrea Christopher, head of Corporate Communications and Investor Relations for Arenaforms Instituticals. Thank you. You may now begin. Thank you, Operator, and thank you to everyone for joining today's call and webcast. Joining me on the call this morning are Peter Greenleaf, Arena's President and Chief Executive Officer, Joe Miller, our Chief Financial Officer, and Dr. Greg Keenan, our Chief Medical Officer. Today, we will review and discuss ARINIA's 2024 third quarter financial and operational results, as communicated in the company's press release issued this morning. The company also filed its quarterly financial statements on Form 10-Q this morning. For more information, please refer to ARINIA's filings with the U.S. Securities and Exchange Commission and Canadian securities authorities, which are also available on ARINIA's website at ARINIApharma.com. During today's call, ARINIA may make forward-looking statements based on current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and actual results may differ materially. For discussion of factors that could affect Arrhenius' future financial results and business, please refer to the disclosures in Arrhenius' press release, its quarterly report on Form 10-Q, and its annual report on Form 10-K, and all of its recent filings wi...